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Background: Triple negative breast cancer encompasses several biological entities with different out-
comes and is a priority to identify which patients require more treatment to reduce the risk of recurrence
and which patients need less treatment.
Patients and methods: Among the 210 women with first primary invasive apocrine non metastatic breast
cancer operated on between January 1998 and December 2016 at the European Institute Oncology, Milan,
we identified 24 patients with a pT1-pT2, node-negative, triple negative subtype and Ki-67  20% who
did not receive adjuvant chemotherapy (CT). We compared the outcome of this cohort with a similar
group of 24 patients with ductal tumors who received adjuvant chemotherapy, matched by pathological
stage and biological features and also with a similar group of 12 patients with apocrine tumors who
received adjuvant chemotherapy.
Results: The median age was 64 and 61 years in the apocrine (w/o CT) and ductal group, respectively. The
median value of Ki-67 expression was 12% in the apocrine group (w/o CT) and 16% in the ductal group
(p < 0.001). After a median follow-up of 7.5 years, no patients in the apocrine group (w/o CT) experienced
a breast cancer related event compared with 4 events in the ductal carcinoma group (Gray test p-
value ¼ 0.11).
Conclusions: The outcome of selected apocrine triple negative breast cancer patients who did not
received adjuvant chemotherapy is excellent and supports a treatment de-escalation. Multicenter pro-
jects focusing on the possibility of avoiding adjuvant chemotherapy in selected subtypes of triple
negative breast cancers with favorable outcome are warranted.
© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Triple negative breast cancer (TNBC) is defined by the absence of
immunostaining for estrogen receptor (ER), progesterone receptor
(PgR) and human epidermal growth factor receptor 2 (HER2).
Generally, TNBCs are more likely to have aggressive features and
exhibit an invasive phenotype with rapid progression; for this
subgroup of tumors chemotherapy remains critical in reducing theology, European Institute of
gna).
an open access article under the Crisk of recurrence [1,4]. Three-year invasive disease-free survival
(IDFS) rates of 81% have been reported for patients with TNBC who
have received adjuvant anthracycline/taxanetherapy [4]. However,
emerging data clearly indicate that TNBC is a heterogeneous dis-
ease with variable prognosis according to clinical, pathologic, and
genetic factors. In particular, histologic subtypes might play a role
in the outcome [5]. If compared with invasive ductal carcinoma
with similar biological features and stages, it is possible to identify
TNBCs with extremely good or extremely poor prognoses. In a
previous study at the European Institute of Oncology (IEO) we
investigated the outcome of 781 patients with TNBC.We reported a
five-year disease free survival (DFS) of 56% in patients with meta-
plastic tumors. Conversely, the five-year DFS for patients withC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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outcome for different subtypes of TNBC indicates that TNBC en-
compasses several biological entities and for a minority of cases
should be possible to avoid adjuvant chemotherapy. Focal apocrine
differentiation is a common feature in invasive carcinoma. How-
ever, apocrine carcinoma is a rare form of breast malignancy,
comprising ~1% of all breast cancers [7]. Apocrine tumors are
typically ER, PgR and HER2 negative and express androgen receptor
[8]. One study suggested a better outcome of apocrine tumors with
distinct clinic-pathological entity and a less aggressive behavior [8].
In our previous experience, the apocrine tumors had a similar
outcome if compared with ductal carcinomas. Similarly Takeuchi
et al. reported no difference in survival rates between apocrine
carcinoma and non apocrine carcinoma at 10 years after surgery [9].
In our study we focused the attention on a selected group of
apocrine TNBC to value the role of a de-escalation treatment. In
particular, we decided to investigate the outcome of patients with
apocrine TNBC with pT1-pT2, low Ki-67 expression and node
negative who underwent to radical surgery. These patients were
not candidate to adjuvant chemotherapy after interdisciplinary
evaluation. The outcome of this group of patients was compared
with those of a ductal carcinoma patients group with similar
pathological stage and biological features, who received adjuvant
chemotherapy, and also with those of an apocrine carcinoma pa-
tients group with similar pathological stage and biological features,
who received adjuvant chemotherapy.2. Materials and methods
2.1. Study patients
All consecutive women operated for breast cancer at IEO were
referred for interdisciplinary evaluation and their data were
included in the institutional database. We selected the ductal and
apocrine breast cancer patients. We extracted information for
29,237 ductal and 210 apocrine early breast cancer patients oper-
ated between January 1998 and December 2016. We included in
our analysis only women with available characterization of breast
cancer (i.e., with evaluation of ER, PgR, HER2 and Ki-67), without aTable 1
Biological and clinical features of apocrine (w/o CT) and ductal (w CT) tumors.
Apocrine w/o CT
N ¼ 24
N %
Year of surgery
Before 2003 0 e
2003e2006 6 25
2007e2010 7 29
After 2010 11 46
Menopausal status
Premenopausal 1 4
Postmenopausal 23 96
pT
pT1 20 83
pT2 4 17
Local treatment
Quadrantectomy w/o RT 1 4
Quadrantectomy w RT 21 88
Mastectomy w/o RT 2 8
Mastectomy w RT 0 e
Peritumoral vascular invasion
No 24 100
Yes 0 e
Age median (IQR) 64.3 (58.2e66.9)
Ki67 median (IQR) 12.0 (10.0e15.0)previous primary tumor andwithout a preoperative chemotherapy.
The shared selection criteria were: triple negative subtype, pT1-
pT2, node-negative tumor, and Ki-67  20%. Both apocrine tumor
who did not receive adjuvant chemotherapy and who received
adjuvant chemotherapy and ductal carcinomas who received
adjuvant chemotherapy were considered.
Twenty-four patients with apocrine tumors who did not
received adjuvant chemotherapy and 26 patients with ductal tu-
mors who received adjuvant chemotherapy fulfilled the inclusion
criteria for the analysis. In order to have two balanced groups, a
cohort of 24 women with ductal tumors was randomly extracted
and matched (1:1 ratio) to the apocrine cohort who did not
received adjuvant chemotherapy. A third group of 12 apocrine tu-
mors who received adjuvant chemotherapy fulfilled the inclusion
criteria and was included for supplementary analysis.
Flowchart for apocrine groups selection was reported in Sup-
plementary Figure 1.
Pure apocrine differentiation was diagnosed according to WHO
tumors classification morphological criteria and to immunoprofile
status, ER and PgR negative and androgen receptor (AR) positive, as
previously described [10].2.2. Statistical methods
Categorical variables were reported with absolute and relative
frequencies; continuous variables were reported with median and
interquartile range (IQR). Fisher’s exact test and Wilcoxon rank-
sum test were used to compare categorical and continuous vari-
ables, respectively.
The endpoints evaluated were invasive disease-free survival
(IDFS), overall survival (OS) and cumulative incidence of invasive
breast cancer related events (IBCRE). Events considered in the IDFS
computations were invasive relapse, appearance of a second pri-
mary cancer, or death, whichever occurred first. OS was defined as
the time from surgery until the date of death (from any cause).
Events considered for IBCRE were loco-regional relapses, contra-
lateral relapses and distant metastases. Surviving patients were
censored at the last follow-up visit.
The IDFS and OS functions were estimated using theMatched ductal w CT
N ¼ 24
P-value
N %
0.01
8 33
4 17
5 21
7 29
0.02
8 33
16 67
0.49
17 71
7 29
0.54
0 e
20 83
2 8
2 8
0.11
20 83
4 17
61.2 (45.5e64.5) 0.04
16.0 (13.0e17.5) <0.001
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ferences between groups.
The IBCRE curve function was estimated according to methods
described by Kalbfleisch and Prentice, taking into account the
competing causes of recurrence (not breast related events). The
Gray’s test was used to assess cumulative incidence differences
between groups.
All analyses were performed with SAS software v. 9.4 (SAS
Institute, Cary, NC). All tests were two-sided and p-values <0.05
were considered statistically significant.Fig. 2. Cumulative incidence of breast-related events in apocrine (w/o CT) and ductal
(w CT) carcinoma.3. Results
Table 1 reports the clinical and biological features of apocrine
group who did not received adjuvant chemotherapy and ductal
carcinoma group who received adjuvant chemotherapy. The me-
dian age was 64 and 61 years in the apocrine and ductal group,
respectively (p ¼ 0.04). The median value of Ki-67 expression was
12% in the apocrine group and 16% in the ductal group (p < 0.001)
96% of apocrine breast patients were inmenopausal comparedwith
67% of patients in the ductal group (p ¼ 0.02). No significant dif-
ferences were reported for the tumor size between apocrine and
ductal carcinoma since in both groups most patients had breast
tumor size less than 2 cm: 83% of apocrine and 71% of ductal
(p ¼ 0.49).
Median follow-up was 7.5 years.
All patients with ductal carcinoma received adjuvant chemo-
therapy. Specifically, 18 patients received CMF for six cycles (75%), 1
patient received metronomic cyclophosphamide and methotrexate
(4.2%), 4 patients received anthracycline based chemotherapy
(16.6%), 1 patient received taxane chemotherapy (4.2%).
Fig.1A shows the IDFS in both group. The 5-years IDFS was 80.1%
for apocrine and 91.1% for ductal. In details, 3 events were reported
in the apocrine group (1 death not cancer related as first event and
2 other primitive cancers) and 6 events in the ductal group (3 loco-
regional recurrences, 2 other primitive cancers and 1 contralateral
breast cancer). The 5-years OS was 92.9% and 100% in the apocrine
and ductal carcinoma group, respectively, as shown in Fig. 1B. Fig. 2
shows the cumulative incidence of IBCRE in both groups. In detail:
no patients in the apocrine group experienced an invasive breast
cancer related event compared with 4 events (including 3 loco-Fig. 1. Invasive disease-free survival (A) and overall survivalregional recurrences and 1 contralateral tumors) in the ductal
carcinoma group (Gray test p-value ¼ 0.11). All these 4 patients
with ductal carcinoma that experienced breast-related events
received CMF for six cycles.
Supplementary Table 1 reports the clinical and biological fea-
tures of apocrine groups with and without adjuvant chemotherapy.
Supplementary Figure 2A shows the IDFS in apocrine groups
with and without adjuvant chemotherapy. The 5-years IDFS for
apocrine tumors that received adjuvant chemotherapy was 80.8%;
3 events were reported: 1 invasive contralateral breast recurrence,
1 invasive ipsilateral breast recurrence and 1 other primitive can-
cer. No differences in the IDFS for apocrine carcinoma with and
without adjuvant chemotherapy was observed (Log-rank p-
value ¼ 0.814). Supplementary Figure 3 shows the cumulative(B) in apocrine (w/o CT) and ductal (w CT) carcinoma.
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chemotherapy. In the apocrine group that received adjuvant
chemotherapy, 2 breast-related events were reported: 1 invasive
contralateral breast recurrence, 1 invasive ipsilateral breast recur-
rence (Gray test p-value ¼ 0.10).
The adjuvant chemotherapy in special types of apocrine tumors
was prescribed more frequently during the initial years (i.e. before
2010) and in younger patients [Median age (IQR) 64.3 years
(58.2e66.9) in the no adjuvant chemotherapy group and 60.8 years
(44.0e65.6) in the chemotherapy group.]
4. Discussion
TNBC encompasses several biological entities with different
outcomes. In this heterogeneous scenario, it is a priority to identify
which patients require more treatment to reduce the risk of
recurrence and which patients need less treatment. The reported
prevalence of apocrine carcinomamarkedly differs between several
reports and ranges from 0.4% to 62% [11e14].
This considerable variability seems to occur because of the
absence of a uniform definition of apocrine carcinoma. Such a
definition would be important to distinguish apocrine tumors from
apocrine-like carcinomas, the latter predominantly belonging to
the luminal phenotype [15,16].
The absence of standardized criteria and the suboptimal
reproducibility of the histopathologic classification limits the use of
available information on special types of breast cancer in tailoring
adjuvant therapy [17].
In addition to these observations, our study is unique in that it
evaluates the outcome of special types of breast cancer within the
apocrine tumor subgroups and this includes the large (albeit
limited) number of patients who are not treated with adjuvant
chemotherapy. Moreover, this is a single institution study. All
included patients had a histological evaluation carried out at the
IEO by the same team of pathologists thereby ensuring consistent
pathological reporting. The median follow-up was 7.5 years which
should also be considered appropriate for the triple-negative
group.
Of the apocrine group who did not receive chemotherapy, none
of the patietns experienced an invasive breast cancer related event
compared with 4 events (including 3 loco-regional recurrences and
1 contralateral tumors) in the ductal carcinoma group (Gray test p-
value ¼ 0.11). All these 4 patients with ductal carcinoma who
experienced breast-related events received CMF for six cycles. This
regime was administered primarily in earlier years in place of
anthracycline and taxane chemotherapy which represents the
current standard of care for TNBC: In our sample, 70% of patients in
the ductal group underwent surgery before 2010. Morevoer no
difference in the IDFS for apocrine carcinoma with or without
adjuvant chemotherapy was observed (Log-rank p-value ¼ 0.814)
confirming the possibility to spare chemotherapy in selected TNBC
patients.
On the other hand, data indicate that it is possible to identify by
gene expression array a molecular apocrine breast cancer subtype
characterized by the expression of androgen receptor and the
absence of estrogen receptor [18]. One third of these cases are also
HER2 negative.
Some of these tumors, but not all, are morphological hallmarks
of apocrine. Recently the outcome of patients with molecular
apocrine breast cancer included in the preoperative EORTC1099
study was analyzed. The Authors identified ninety-three cases with
molecular apocrine subtype between the 846 eligible patients.
Within the molecular apocrine subtype the 5-years recurrence free
interval was 59% and the authors concluded that the outcome re-
mains poor and suggested adjuvant trials be conducted to evaluateantiandrogens [19].
The results of our study indicate that an accurate and reliable
histopathologic assessment is crucial in order to detect special
types of cancer. The prognosis of selected apocrine triple negative
breast cancer patients may be favorable even in the absence of
adjuvant chemotherapy.
In our series, as previously reported, apocrine tumors were
diagnosed more often in older women than was ductal carcinoma;
the median age was 64 vs 61 years in the apocrine and ductal
groups, respectively. The lack of need for chemotherapy should be
particularly relevant as older women have a greater probability of
having concomitant disease and treatments. However, the retro-
spective nature of our study and the very low number of patients
does not allow us to draw definite conclusions regarding the
prognosis of special types of TNBC. To support a treatment de-
escalation in selected groups of special types of breast cancer,
multicenter projects are warranted. Such tailored research will
require international cooperation to solidify consensus on how to
treat or not individual patients with special types of breast cancer.
5. Conclusion
The outcome of selected apocrine triple negative breast cancer
patients is excellent and supports a treatment de-escalation.
Multicenter projects focusing on the possibility of avoiding adju-
vant chemotherapy in selected subtypes of triple negative breast
cancers with favorable outcome are warranted.
We would like to thank William Russell-Edu for his assistance
with the English text.
Funding source
No funding source for the study.
Ethical approval
This article does not contain any studies with animals per-
formed by any of the authors.
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable
ethical standards.
Declaration of competing interest
Emilia Montagna and Giuseppe Cancello received a honorarium
for consultant/advisory role from Pierre Fabre.
Elisabetta Munzone received a honorarium for consultant/
advisory role from Pierre Fabre and Genomic health.
Giuseppe Viale has received a honorarium for consultant/advi-
sory role from Dako, Roche, Astellas Pharma, Novartis and he has
received funding from Roche, Ventane, Dako.
Marco Colleoni has received a honorarium for consultant/advi-
sory role from Novartis, Pierre Fabre, Pfizer, Obi-Pharma, Puba
biotechnology, Celldex, Astrazeneca.
Eleonora Pagan, Vincenzo Bagnardi, Silvia Dellapasqua, Monica
Iorfida, Manueliata Mazza, Giovanni Mazzarol, Paolo Veronesi,
Viviana Galimberti, Giorgia Santomauro have no conflict of interest.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.breast.2020.07.003.
E. Montagna et al. / The Breast 53 (2020) 138e142142References
[1] Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The
epidemiology of triple-negative breast cancer, including race. Cancer Causes
Control 2009;Sep;20(7):1071e82.
[4] Irshad S, Ellis P, Tutt A. Molecular heterogeneity of triple-negative breast
cancer and its clinical implications. Curr Opin Oncol 2011;23:566e77.
[5] Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A,
et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to
inform the outcome. Clin Breast Canc 2013;Feb;13(1):31e9. 10.1016.
[6] Page DL. Special types of invasive breast cancer, with clinical implications. Am
J Surg Pathol 2003;27:832e5.
[7] Mills AM1, E Gottlieb C, Wendroth S M, Brenin C M, Atkins KA. Pure apocrine
carcinomas represent a clinicopathologically distinct androgen receptor-
positive Subset of triple-negative breast cancers. Am J Surg Pathol Aug
2016;40(8):1109e16.
[8] Takeuchi H, Tsuji K, Ueo H, et al. Clinicopathological features and long-term
prognosis of apocrine carcinoma of the breast in Japanese women. Breast
Canc Res Treat 2004;88:46e54.
[9] Dellapasqua S, Maisonneuve P, Viale G, Pruneri G, et al. Immunohistochemi-
cally defined subtypes and outcome of apocrine breast cancer. Clin Breast
Canc 2013;Apr;13(2):95e102.
[10] Gayatri G, Mondita B, Asha B, Vishal A. Study on apocrine carcinoma of
breast: histomorphologic features and immunohistochemical behavior. In-
ternational Journal of Basic and Applied Medical Sciences 2012;2(3):190e3.
[11] Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinomadrare types: reviewof the literature. Ann Oncol 2009;20(11):1763e70.
[12] Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG. Apocrine carcinoma
of the breast. A morphologic and immunocytochemical study. Am J Pathol
1986;1986 Jun;123(3):532e41. Erratum in: Am J Pathol Sep;124(3):following
563.
[13] Japaze H, Emina J, Diaz C, Schwam RJ, Gercovich N, Demonty G, Morgenfeld E,
Rivarola E, Gil Deza E, Gercovich FG. Pure’ invasive apocrine carcinoma of the
breast: a new clinicopathological entity? Breast. Feb 2005;14(1):3e10.
[14] Tsutsumi Y. Apocrine carcinoma as triple-negative breast cancer: novel defi-
nition of apocrine-type carcinoma as estrogen/progesterone receptor-
negative and androgen receptor-positive invasive ductal carcinoma. Jpn J
Clin Oncol 2012;42(5):375e86.
[15] Durham JR, Fechner RE. The histologic spectrum of apocrine lesions of the
breast. Am J Clin Pathol 2000;113(supplement 1):S18. S3.
[16] Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is
there a unifying taxonomy? Nat Rev Clin Oncol 2009;6:718e30.
[17] Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, et al. Identification of
molecular apocrine breast tumours by microarray analysis. Oncogene
2005;24:4660e71.
[18] Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, et al. A refined mo-
lecular taxonomy of breast cancer. Oncogene 2012;mar 1;31(9):1196e206.
[19] Bonnefoi H, MacGrogan G, Poncet C, Iggo R, et al. EORTC 10994/BIG 1-00 study
investigators. Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III
study: pathological response after neoadjuvant chemotherapy and clinical
outcomes. Br J Cancer. Apr 2019;120(9):913e21.
